| Vertex Pharmaceuticalsannounced 3 Aug 2026 |
Close the acquisition of Crinetics Pharmaceuticals, Inc |
Being checked30 Sep 2026 |
| Vertex Pharmaceuticalsannounced 3 Aug 2026 |
Share proof-of-concept results for VX-828 in people with cystic fibrosis |
Open31 Dec 2026 |
| Vertex Pharmaceuticalsannounced 3 Aug 2026 |
Complete full enrollment in the AMPLITUDE study of APOL1 inhibitors |
Open31 Dec 2026 |
| Vertex Pharmaceuticalsannounced 3 Aug 2026 |
Complete enrollment in the Phase 2 povetacicept study in generalized myasthenia gravis |
Open31 Dec 2026 |
| Vertex Pharmaceuticalsannounced 3 Aug 2026 |
Share interim analysis data from the AMPLITUDE study |
Open30 Jun 2027 |
| Vertex Pharmaceuticalsannounced 4 Aug 2025 |
Submit global regulatory applications for zimislecel in type 1 diabetes |
Open31 Dec 2026 |
| Vertex Pharmaceuticalsannounced 4 Aug 2025 |
Complete enrollment in both DPN Phase 3 studies of suzetrigine |
Open31 Dec 2026 |
| Vertex Pharmaceuticalsannounced 10 Feb 2025 |
Begin shipping JOURNAVX to pharmacies nationwide |
No record found28 Feb 2025 |
| Vertex Pharmaceuticalsannounced 10 Feb 2025 |
Complete dosing of children aged 5 to 11 in two Phase 3 CASGEVY studies |
Being checked31 Dec 2025 |
| Vertex Pharmaceuticalsannounced 10 Feb 2025 |
Complete enrollment in the interim analysis cohort of the AMPLITUDE trial of inaxaplin |
Met31 Dec 2025 |
| Vertex Pharmaceuticalsannounced 4 Nov 2024 |
Share results from the Phase 2 study of suzetrigine in lumbosacral radiculopathy |
Met31 Dec 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2024 |
Initiate a Phase 2 study of oral VX-993 in painful diabetic peripheral neuropathy |
No record found30 Sep 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2024 |
Initiate a Phase 2 study of oral VX-993 in moderate to severe acute pain after bunionectomy |
No record found30 Sep 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2024 |
Initiate the Phase 3 pivotal program of suzetrigine in painful diabetic peripheral neuropathy |
No record found30 Sep 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2024 |
Initiate the Phase 3 RAINIER trial of povetacicept in IgA nephropathy |
No record found30 Sep 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2024 |
Complete the VX-522 Phase 1/2 study and share its data |
Not met30 Jun 2025 |
| Vertex Pharmaceuticalsannounced 5 Feb 2024 |
Submit global regulatory filings for vanzacaftor triple, including an NDA to the FDA and MAAs to EMA and Health Canada |
Met30 Jun 2024 |
| Vertex Pharmaceuticalsannounced 5 Feb 2024 |
Submit a New Drug Application to the U.S. FDA for VX-548 in moderate to severe acute pain |
No record found30 Jun 2024 |
| Vertex Pharmaceuticalsannounced 5 Feb 2024 |
Submit regulatory application for CASGEVY in Canada for SCD and TDT |
No record found30 Jun 2024 |
| Vertex Pharmaceuticalsannounced 5 Feb 2024 |
Initiate a Phase 2 study of oral VX-993 for peripheral neuropathic pain |
No record found31 Dec 2024 |
| Vertex Pharmaceuticalsannounced 5 Feb 2024 |
Complete IND-enabling studies and file an IND for an intravenous formulation of VX-993 |
No record found31 Dec 2024 |
| Vertex Pharmaceuticalsannounced 1 Aug 2023 |
Complete the 12-week Phase 2 VX-548 study in diabetic peripheral neuropathy |
Met31 Dec 2023 |
| Vertex Pharmaceuticalsannounced 1 Aug 2023 |
Complete the SAD study and initiate a MAD study of VX-522 |
Met31 Dec 2023 |
| Vertex Pharmaceuticalsannounced 1 Aug 2023 |
Share results of the SKYLINE and RIDGELINE studies |
No record found30 Jun 2024 |
| Vertex Pharmaceuticalsannounced 7 Feb 2023 |
Complete the rolling U.S. biologics license application submission for exa-cel |
No record found31 Mar 2023 |
| Vertex Pharmaceuticalsannounced 7 Feb 2023 |
Complete the single ascending dose study and start the MAD study for VX-522 |
Met31 Dec 2023 |
| Vertex Pharmaceuticalsannounced 7 Feb 2023 |
Complete the Phase 2B dose-ranging portion of the inaxaplin study |
No record found31 Dec 2023 |
| Vertex Pharmaceuticalsannounced 7 Feb 2023 |
Begin Part C of the VX-880 study with concurrent dosing |
No record found31 Dec 2023 |
| Vertex Pharmaceuticalsannounced 4 Aug 2022 |
Initiate the Phase 3 acute pain program for VX-548 |
No record found31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 4 Aug 2022 |
Submit global regulatory filings for TRIKAFTA/KAFTRIO in children aged 2 to 5 |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 4 Aug 2022 |
Initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 4 Aug 2022 |
Submit exa-cel regulatory applications for SCD and TDT in Europe and the UK |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 5 May 2022 |
Submit regulatory filings for ORKAMBI in Europe |
No record found30 Jun 2022 |
| Vertex Pharmaceuticalsannounced 5 May 2022 |
Advance VX-548 into pivotal development in acute pain |
No record found31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 5 May 2022 |
Submit global regulatory filings for CTX001 in TDT and SCD |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 2 Nov 2021 |
Submit an IND for the type 1 diabetes cells and immunoprotective device program |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 2 Nov 2021 |
Submit regulatory filings for CTX001 in beta thalassemia and sickle cell disease |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 2 Nov 2021 |
Advance one or more novel zAAT correctors into the clinic |
No record found31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 2 Nov 2021 |
Submit an IND for the CF mRNA program in collaboration with Moderna |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 29 Jul 2021 |
Begin Phase 3 study of next-in-class triple combination for cystic fibrosis |
Met31 Dec 2021 |
| Vertex Pharmaceuticalsannounced 29 Jul 2021 |
Report data from the VX-548 bunionectomy acute pain trial |
Met31 Mar 2022 |
| Vertex Pharmaceuticalsannounced 29 Jul 2021 |
Report initial data from the VX-880 islet cell Phase 1/2 study |
Met31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 29 Jul 2021 |
Advance novel small molecule zAAT corrector into the clinic |
No record found31 Dec 2022 |
| Vertex Pharmaceuticalsannounced 29 Apr 2021 |
Report results from the Phase 2 proof-of-concept study of VX-864 in Z-AAT deficiency |
Met30 Jun 2021 |
| Vertex Pharmaceuticalsannounced 29 Apr 2021 |
Advance VX-548 into Phase 2 proof-of-concept studies for acute pain |
No record found31 Dec 2021 |
| Vertex Pharmaceuticalsannounced 29 Apr 2021 |
Complete enrollment in the CTX001 clinical studies for sickle cell disease and beta thalassemia |
No record found31 Dec 2021 |
| Vertex Pharmaceuticalsannounced 1 Feb 2021 |
Initiate a Phase 1/2 clinical trial of the VX-880 islet cell therapy |
No record found30 Jun 2021 |
| Vertex Pharmaceuticalsannounced 29 Oct 2020 |
Report clinical data from more patients treated with CTX001 and longer follow-up |
Met31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 29 Oct 2020 |
File a supplemental New Drug Application with the FDA for TRIKAFTA in children aged 6-11 |
No record found31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 29 Oct 2020 |
Report Phase 2 proof-of-concept data for the Z-AAT corrector VX-864 |
Met30 Jun 2021 |
| Vertex Pharmaceuticalsannounced 29 Oct 2020 |
Report Phase 2 proof-of-concept data for VX-147 in APOL1-mediated FSGS |
Met31 Dec 2021 |
| Vertex Pharmaceuticalsannounced 30 Jul 2020 |
Report data from additional patients in the CTX001 gene-editing therapy studies with CRISPR Therapeutics |
No record found31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 30 Jul 2020 |
Submit an Investigational New Drug application to the U.S. FDA for the islet cell program |
No record found31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 29 Apr 2020 |
Submit a supplemental New Drug Application to the U.S. FDA for children ages 6-11 with at least one F508del mutation |
No record found31 Dec 2020 |
| Vertex Pharmaceuticalsannounced 29 Apr 2020 |
Provide additional clinical data from the two ongoing Phase 1/2 studies of CTX001 with partner CRISPR Therapeutics |
No record found31 Dec 2020 |